For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
In the latest session, Surgery Partners Inc (NASDAQ: SGRY) closed at $21.13 up 0.09% from its previous closing price of $21.11. In other words, the price has increased by $0.09 from its previous closing price. On the day, 1.14 million shares were traded. SGRY stock price reached its highest trading level at $21.595 during the session, while it also had its lowest trading level at $20.885.
Ratios:
For a deeper understanding of Surgery Partners Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.83 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.45. For the most recent quarter (mrq), Quick Ratio is recorded 1.78 and its Current Ratio is at 1.93. In the meantime, Its Debt-to-Equity ratio is 2.22 whereas as Long-Term Debt/Eq ratio is at 2.13.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 16 ’25 when Wayne DeVeydt bought 52,946 shares for $21.38 per share.
Wayne DeVeydt bought 25,076 shares of SGRY for $526,899 on Oct 15 ’25. On Oct 14 ’25, another insider, Wayne DeVeydt, who serves as the former director of the company, bought 25,000 shares for $20.54 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGRY now has a Market Capitalization of 2709064704 and an Enterprise Value of 8162626048. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.84 while its Price-to-Book (P/B) ratio in mrq is 1.55. Its current Enterprise Value per Revenue stands at 2.522 whereas that against EBITDA is 12.657.
Stock Price History:
The Beta on a monthly basis for SGRY is 1.86, which has changed by -0.36008477 over the last 52 weeks, in comparison to a change of 0.13033986 over the same period for the S&P500. Over the past 52 weeks, SGRY has reached a high of $33.37, while it has fallen to a 52-week low of $18.87. The 50-Day Moving Average of the stock is -3.94%, while the 200-Day Moving Average is calculated to be -6.41%.
Shares Statistics:
For the past three months, SGRY has traded an average of 1.48M shares per day and 1278350 over the past ten days. A total of 128.21M shares are outstanding, with a floating share count of 75.98M. Insiders hold about 40.74% of the company’s shares, while institutions hold 73.72% stake in the company. Shares short for SGRY as of 1759190400 were 12278805 with a Short Ratio of 8.30, compared to 1756425600 on 12685090. Therefore, it implies a Short% of Shares Outstanding of 12278805 and a Short% of Float of 20.31.
Earnings Estimates
A comprehensive evaluation of Surgery Partners Inc (SGRY) is underway, with the input of 11.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.48, with high estimates of $0.61 and low estimates of $0.36.
Analysts are recommending an EPS of between $1.06 and $0.57 for the fiscal current year, implying an average EPS of $0.85. EPS for the following year is $1.01, with 11.0 analysts recommending between $1.65 and $0.69.
Revenue Estimates
A total of 11 analysts believe the company’s revenue will be $822.69M this quarter.It ranges from a high estimate of $839.4M to a low estimate of $803.8M. As of. The current estimate, Surgery Partners Inc’s year-ago sales were $770.4MFor the next quarter, 11 analysts are estimating revenue of $932.16M. There is a high estimate of $951.2M for the next quarter, whereas the lowest estimate is $904.35M.
A total of 11 analysts have provided revenue estimates for SGRY’s current fiscal year. The highest revenue estimate was $3.39B, while the lowest revenue estimate was $3.32B, resulting in an average revenue estimate of $3.36B. In the same quarter a year ago, actual revenue was $3.11BBased on 11 analysts’ estimates, the company’s revenue will be $3.69B in the next fiscal year. The high estimate is $3.77B and the low estimate is $3.62B.
